-
1 Comment
Amoy Diagnostics Co., Ltd is currently in a long term uptrend where the price is trading 26.0% above its 200 day moving average.
From a valuation standpoint, the stock is 212.5% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 30.1.
Amoy Diagnostics Co., Ltd's total revenue rose by 21.2% to $201M since the same quarter in the previous year.
Its net income has increased by 70.3% to $45M since the same quarter in the previous year.
Finally, its free cash flow grew by 365.0% to $60M since the same quarter in the previous year.
Based on the above factors, Amoy Diagnostics Co., Ltd gets an overall score of 4/5.
| Exchange | SHE |
|---|---|
| CurrencyCode | CNY |
| Sector | Healthcare |
| ISIN | CNE1000034D3 |
| Industry | Diagnostics & Research |
| Market Cap | 8B |
|---|---|
| PE Ratio | 29.11 |
| Dividend Yield | 0.7% |
| Beta | 0.91 |
| Target Price | 29.816 |
Amoy Diagnostics Co., Ltd. engages in the development and commercialization of diagnostics product for oncology in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers, and advances targeted treatment research in ovarian cancer; AmoyDx HRD complete panel, detects genetic aberrations across HRR genes and HRD status; AmoyDx master panel, a CGP assay; AmoyDx BRCA Pro panel, covers various protein coding regions, intron/exon boundaries, select introns, and UTR regions of the BRCA1 and BRCA2 genes; AmoyDx handle classic NGS panel, detects multiple gene mutations in cancer patients for treatment; and AmoyDx essential NGS panel, detects EGFR, ALK, ROS1, RET, KRAS, NRAS, PIK3CA, BRAF, HER2, and MET genes in patients with non-small cell lung cancer and colorectal cancer using FFPE or liquid biopsy samples. It also provides AmoyDx handle HRR NGS panel for detection of somatic and germline variants; AmoyDx pan lung cancer PCR panel, a tissue-based real-time qPCR assay for in vitro diagnostics; AmoyDx myeloid blood cancer panel; AmoyDx comprehensive panel, a sequencing-based test capable of detecting a range of alterations; AmoyDx PD-L1 (E1L3N) assay; and AmoyDx handle melanoma NGS panel, detects single nucleotide variants, insertions, and deletions within pivotal melanoma tumor genes. In addition, the company offers ALK gene fusions and ROS1 gene fusions, multi-gene mutations, EML4-ALK fusion gene, EGFR/ALK/ROS1 mutations, MET mutation, HER2 mutation, RET gene fusions, KRAS mutation, KRAS/NRAS mutations, NRAS mutation, KRAS/NRAS/BRAF mutations, BRAF mutation, PIK3CA five mutations, microsatellite instability, PIK3CA mutation, human papillomavirus genotyping, JAK2 mutation, TERT/HRAS mutations, EGFR 29 mutations, EGFR mutation, ROS1 gene fusions, NTRK gene fusions, BRAF V600 mutations detection kits, as well as DNA and RNA extraction kits under the Super-ARMS and AmoyDx names. The company was founded in 2008 and is ba
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300685.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
